Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.
about
Ethics in nanomedicineSafety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma.Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle.Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubblesLiposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.Cardiotoxicity of cancer therapy.Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish.Liposomal cancer chemotherapy: current clinical applications and future prospects.Liposomally targeted cytotoxic drugs for the treatment of cancer.Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review.Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies.Influence of tumour size on uptake of(111)ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model.Lipopeptide delivery of siRNA to the central nervous system.Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine.Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease
P2860
Q28389241-DD28843E-1D65-4AEF-9254-3DA0B033EE5EQ30380999-3730D15F-035F-44AE-841D-83E2EE72AA6EQ30490507-7F3A04D0-EBD7-4ECA-8A1A-13311D28E1E9Q30499622-38D99DE9-02C3-4907-AD40-B3A4C8030219Q33230304-4FE3F138-FFBF-48B6-8F84-6039AF6B1B2BQ33704056-6CAF1A0D-911D-4593-8772-CCD01427A1FAQ33857633-D1348BB4-4B04-4DE0-9C0B-32597D825662Q34481466-EE5AA085-EC23-44BF-8CE8-7B6AA7F22658Q35051019-1F37CC29-895B-4095-B0AB-F60B0A685309Q36532263-A96AE120-EE14-4A17-9554-E02E4C9A8CC6Q36621692-F9BAAD0E-4537-4AC2-B551-5EC3D80F7B74Q36621814-A7E7713D-DC7C-47D2-A5F5-D4A46C2C0CD7Q46250876-A6C376BA-2A4D-49A2-930C-CB607330E12AQ53477596-4AB39DE4-0538-4278-9D8D-6734938D64B3Q57779775-725CDECF-29D5-4D4D-94EE-71F89F81B7FD
P2860
Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Efficacy and safety of Stealth ...... ernational SL-DOX Study Group.
@ast
Efficacy and safety of Stealth ...... ernational SL-DOX Study Group.
@en
type
label
Efficacy and safety of Stealth ...... ernational SL-DOX Study Group.
@ast
Efficacy and safety of Stealth ...... ernational SL-DOX Study Group.
@en
prefLabel
Efficacy and safety of Stealth ...... ernational SL-DOX Study Group.
@ast
Efficacy and safety of Stealth ...... ernational SL-DOX Study Group.
@en
P2093
P2860
P356
P1476
Efficacy and safety of Stealth ...... ernational SL-DOX Study Group.
@en
P2093
Goldstein D
Jablonowski H
Stewart JS
P2860
P2888
P304
P356
10.1038/BJC.1996.193
P407
P577
1996-04-01T00:00:00Z